U.S. markets closed
  • S&P Futures

    4,430.50
    -2.50 (-0.06%)
     
  • Dow Futures

    34,743.00
    0.00 (0.00%)
     
  • Nasdaq Futures

    15,172.25
    -22.50 (-0.15%)
     
  • Russell 2000 Futures

    2,278.60
    +1.60 (+0.07%)
     
  • Crude Oil

    75.42
    -0.03 (-0.04%)
     
  • Gold

    1,751.10
    -0.90 (-0.05%)
     
  • Silver

    23.74
    +1.08 (+4.76%)
     
  • EUR/USD

    1.1699
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.4840
    +0.0240 (+1.64%)
     
  • Vix

    18.76
    +1.01 (+5.69%)
     
  • GBP/USD

    1.3702
    -0.0003 (-0.02%)
     
  • USD/JPY

    110.9700
    -0.0080 (-0.01%)
     
  • BTC-USD

    42,101.47
    -1,088.16 (-2.52%)
     
  • CMC Crypto 200

    1,042.03
    -59.49 (-5.40%)
     
  • FTSE 100

    7,063.40
    +11.92 (+0.17%)
     
  • Nikkei 225

    30,240.06
    -8.75 (-0.03%)
     

European Commission To Procure 220K Doses Of Glaxo-Vir Biotech's COVID-19 Antibody

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have signed a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of COVID-19 antibody.

  • The agreement covers sotrovimab, an investigational single dose monoclonal antibody for treating adults and adolescents (aged 12 years and over and weighing at least 40 kg) with COVID-19 who do not require oxygen supplementation and are at risk of progressing to severe COVID-19.

  • This action follows the positive scientific opinion issued by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).

  • Sotrovimab is included in the European Commission's portfolio of promising candidate therapies as part of its COVID-19 Therapeutics Strategy.

  • In addition, the documentation to support the forthcoming marketing authorization for sotrovimab is under rolling regulatory review with the EMA.

  • In June, full results from the Phase 3 COMET-ICE trial showed a 79% reduction in hospitalizations for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial.

  • GSK and Vir plan to submit a marketing application to the FDA in 2H of 2021.

  • In May, sotrovimab received an emergency use nod from the FDA for treating mild-to-moderate COVID-19.

  • Price Action: VIR shares closed at $36.44 on Tuesday, while GSK stock is up 0.58% at $39.75 during the premarket session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.